Data and Resource Sharing Plan
It is the philosophy of the group to make all data generated by the laboratory or in collaboration with the laboratory available to the widest potential audience with the least number of restrictions.
Publications arising from these studies where we are the corresponding author will be published in journals meeting the gold open access standards of free availability, and a permissive re-use license (CC-BY or the like). All published data will be submitted to journals indexed by the major biomedical indexing sites including PubMed and PubMed Central.
For all studies the raw data, as well as the relevant metadata and computational algorithms used to generate statistical and graphical summaries which were used to generate the final research data will be provided. This data will be provided with a permissive (CC0 or CC-BY) use license. These data tables of 3-star or higher quality (as defined by Open Data Standards see http://5stardata.info/).
Data will also be deposited as supplementary data to the relevant publications where possible and where permitted, and all raw data, processed data and analysis code will be deposited to web-accessible data repositories such as Zenodo (http://zenodo.com), Figshare (http://figshare.com), Dryad (http://datadryad.org/) or similar services. All next generation sequence files will be deposited into the Gene Expression Omnibus (http://http://www.ncbi.nlm.nih.gov/geo/) and the accession number will be quoted in the manuscript(s). Finally data will be posted on, or linked to, from the principal investigator’s website. If further data is obtained relevant to these studies, which can be combined with the published data sets, these evolving data sets will be added to the available online repositories, separately from the published data sets.
All commercially purchased antibodies, reagents or kits will be clearly described in publications, including catalog or stock numbers. This data will also be provided in the metadata assoicated with published datasets. Reagents, constructs, fruit fly, cell or mouse transgenic lines generated during these studies will be maintained in the principal investigator’s laboratory and made available freely and without restriction to any scientists, providing sufficient amounts are availabe. The only exception to this is if a reagent or line was provided with a restrictive materials transfer agreement, in which case the recipient investigator will be directed to the primary source of the reagent. All publications will direct readers to the source of commercially available resources including catalog numbers